Where now for anti-EGF receptor therapies in colorectal cancer?

Abstract

Current US FDA-approved monoclonal antibodies targeting the EGF receptor (EGFR) include cetuximab and panitumumab. In this article, we discuss the clinical evidence concerning the use of monoclonal antibodies targeting the EGFR in the setting of advanced colorectal cancer and the emergence of predictive molecular biomarkers. In addition, we also consider the evidence surrounding the evolution of anti-EGFR-resistance mechanisms evoked by targeted anti-EGFR therapy and potential therapeutic strategies that may counteract resistant tumor growth.

Keywords::

• biomarkers
• cetuximab
• colorectal cancer
• EGFR
• monoclonal antibody
• panitumumab

Financial & competing interests disclosure

Richard A Adams has received Roche consultancy fees, lecturing fees, and travel and conference fees. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.